Related Experiment Video
Updated: Jan 6, 2026

Author Spotlight: 3D Scanning and Augmented Reality for Enhanced Cancer Surgery Communication
Published on: December 15, 2023
Surgery at High-Quality Hospitals Among Medicare Advantage Beneficiaries Undergoing Cancer Surgery
Avinash Maganty1, Xiu Liu1, Christopher Dall1
1Department of Urology, Massachusetts General Hospital, Boston.
Importance:
Enrollment in Medicare Advantage (MA) accounts for more than half of Medicare beneficiaries. Despite this growth, its impact on access to high-quality cancer surgery remains unclear.
Objective:
To evaluate the association between MA enrollment and receipt of surgery at high-quality hospitals among Medicare beneficiaries undergoing major cancer surgery.
Design, Setting, And Participants:
This national retrospective cohort study uses Medicare Provider Analysis and Review (MedPAR) data from January 1, 2016, to November 30, 2022. The study included 567 770 Medicare beneficiaries undergoing elective surgery for esophageal, pancreatic, liver, gastric, bladder, colon, kidney, or prostate cancer at hospitals across the United States. Data analysis was performed from August 2024 to July 2025.
Exposure:
Enrollment in Medicare Advantage plan.
Main Outcomes And Measures:
The primary outcome was surgery at a high-quality hospital, defined by procedure-specific mortality, risk-adjusted for patient characteristics and reliability-adjusted for differences in case volume using mixed-effects logistic regression models. Adjusted hospital mortality was rank ordered and sorted into quintiles. High quality was defined as hospitals in the quintile with the lowest mortality rates. The secondary outcome was likelihood of bypassing the nearest hospital of lower quality to undergo surgery at a high-quality hospital.
Results:
Among 567 770 beneficiaries undergoing surgery, 351 447 were enrolled in traditional Medicare (TM; 231 104 [65.8%] male, 120 343 [34.2%] female; mean [SD] age, 72.5 [8.0] years) and 216 323 in MA (138 554 [64.0%] male, 77 769 [36.0%] female; mean [SD] age, 72.7 [7.6] years). MA enrollment increased from 32% in 2016 to 46% in 2022. Compared with beneficiaries in TM, MA enrollees were more likely to be from socially vulnerable areas, have more comorbidities, and undergo surgery at nonteaching hospitals across all cancer types. Compared with those in TM, MA beneficiaries were less likely to undergo surgery at a high-quality hospital. For example, 21.7% (95% CI, 20.7%-22.8%) of patients enrolled in TA had an esophagectomy at a high-quality hospital vs 17.3% (95% CI, 16.1%-18.5%) of MA beneficiaries, and 22.6% (95% CI, 22.1%-23.2%) of patients enrolled in TA had a pancreatectomy at a high-quality hospital vs 16.2% (95% CI, 15.6%-16.8%) of those in MA. TM beneficiaries were more likely to bypass a lower-quality hospital to receive surgery at a high-quality hospital for all procedures.
Conclusions And Relevance:
This study found that MA enrollees were less likely to receive cancer surgery at high-quality hospitals and less likely to bypass lower-quality hospitals. These findings suggest that current MA plan networks may limit access to optimal surgical care, raising concerns about the adequacy of cancer care delivery under privatized Medicare.
More Related Videos
03:07Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial
Published on: August 19, 2025
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
Related Concept Videos
Cancer Survival Analysis
Health Information Technology and Healthcare Information System
Health Information Technology, commonly called HIT, integrates advanced information systems and technology in healthcare settings. Its primary functions include:
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...